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Abstract: Pancreatic cancer (PaCa) is a highly metastatic cancer, and patients are at high risk of
developing venous thromboembolism (VTE). Neutrophil extracellular traps (NETs) have been
associated with cancer metastasis and cancer-associated thrombosis, but the ability of cancer to
stimulate NET release is not known. The release of NETs has been shown to be a slow process
and requires reactive oxygen species (ROS) production. Studies suggest that activated platelets are
important mediators in the release. Here, we show that PaCa cells can stimulate the rapid release of
NETs, independently of ROS production. We further assessed the role of platelets in PaCa-induced
NETs and observed a trend of increased the NET release by PaCa-primed platelets. Additionally, NETs
promoted thrombus formation under venous shear stress ex vivo. Taken together, our results suggest
that PaCa-induced NETs can contribute to the high risk of venous thromboembolism development in
PaCa patients, and reveal NETs as a potential therapeutic target.
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1. Introduction
Neutrophil extracellular traps (NETs) are web-like structures composed of DNA and proteins
that are expelled from activated polymorphonuclear neutrophils (PMNs) in response to bacterial or
inflammatory stimuli [1,2]. They were first discovered to serve a protective role in immune defence
as they can entrap pathogens, and directly kill bacteria via NET-bound antimicrobial proteins [2].
However, studies have revealed that NETs are not exclusive to bacterial infection, but are also involved
in inflammatory and autoimmune diseases such as systemic lupus erythematosus, preeclampsia,
rheumatoid arthritis, cystic fibrosis and thrombosis [3–6].
More recently, several links between NETs and cancer have been made. The first study
investigating NETs and their association with cancer established that PMNs isolated from
tumour-bearing mice are sensitised to form NETs [7]. Furthermore, spontaneous thrombi were found
in association with NETs in tumour-bearing mice, suggesting a possible cause of cancer-associated
thrombosis [7]. NETs have also been implicated in cancer progression, where cancer cells were
found entrapped in the vasculature by NETs, which correlated with increased tumour metastases [8].
Not only have NETs been found in tumour-bearing mice [7,9], but also in tumour samples from cancer
patients [9–11]. Despite the association between NETs and cancer, whether or not cancer cells can
directly stimulate the release of NETs has not been investigated.
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The molecular mechanisms of NET generation are poorly understood; however, several studies
suggest that neutrophil–platelet interactions are important. Activated platelets in inflammation
or infection play a vital role in the release of NETs, either by mediating interactions with
neutrophils [12–15] or by soluble mediators released from platelets [16]. Platelets are also known
to become activated and aggregate in cancers and are usually present in high numbers in cancer
patients [17]. Thus platelets may also have a major role in NET release in cancer.
Activated platelets in contact with tumour cells can also recruit neutrophils by secreting
chemokines (C-X-C motif) ligand (CXCL) 2 and CXCL5 chemokines [18]. Platelets are crucial in
recruiting neutrophils in vivo as depleting platelets resulted in complete inhibition of granulocyte
recruitment [18]. Thus, there is evidence to support platelets and their role in recruiting neutrophils
to tumour sites; however little is known about platelets and their role in activating neutrophils in
cancers [19]. Similarly, platelets have been demonstrated to interact with neutrophils and induce NET
generation in bacterial infection, though in the presence of cancer, the importance of platelets in NET
release has not been studied.
Therefore, given the high incidence and morbidity due to thrombotic diseases and metastasis in
pancreatic cancer patients [20,21], this study aimed to investigate the interactions between neutrophils,
platelets and pancreatic cancer cells and their potential contribution to the hypercoagulable state that is
present with cancer-associated thrombosis. The impact of platelets and cancer cells on NETs generated,
as well as the consequences of NETs on platelet activity, were investigated. We report that pancreatic
cancer cells can stimulate the release of NETs, and that this is not dependent on neutrophil–cancer
cell interactions as the protein fraction of cancer cell-conditioned media also induced NET release.
Furthermore, we also show that NETs cause platelet activation and spreading, as well as thrombus
formation under venous flow conditions. This improved understanding of these interactions may help
explain contributors to the high risk of thrombosis in pancreatic cancer, and NETs or unique signalling
events between cells that promote the NET release may serve as novel therapeutical targets.
2. Results
2.1. Pancreatic Cancer Cell Line AsPC-1 Stimulates NET Generation
To determine whether cancer cells can directly stimulate the release of NETs, pancreatic cancer
cell and PMN co-cultures were performed. The metastatic pancreatic cancer cell line AsPC-1 was
incubated with PMNs for 3 h, and NET release was quantified. To quantify NETs, extracellular DNA
(exDNA) was stained with Sytox Green, a cell-impermeable fluorescent dye specific for DNA, and
fluorescence was measured in a plate reader. NETs were quantified at 30 min, and at 3 h, as shown in
Figure 1. AsPC-1 cells efficiently stimulated the release of NETs after incubation with human PMNs.
In addition, NETs were induced by AsPC-1 in a rapid process as a significant 2-fold increase in exDNA
release was observed at 30 min. Positive control, phorbyl myristate acetate (PMA)-stimulated PMNs
required 3 h for significant NET release to occur. AsPC-1 cells were also incubated without PMNs to
determine if AsPC-1 cells produced any exDNA. Sytox Green staining of AsPC-1 cells confirmed that
the increase in exDNA was due to PMNs, as AsPC-1 cells did not carry any exDNA.
2.2. AsPC-1-Induced NETs Are Not Contact-Dependent
To determine whether AsPC-1-induced NETs were mediated through cell–cell contact, or via
soluble mediators from AsPC-1, NETs generated were examined after incubation of PMNs with
conditioned medium from AsPC-1. Similarly, AsPC-1-conditioned medium (AsPC-1 CM) also resulted
in a rapid 2-fold increase in exDNA compared to unstimulated control at 30 min, with no further
increase at 3 h (Figure 2). To confirm that the AsPC-1 CM induced NETs phenomenon is specific to
cancer cells, the conditioned medium of primary mesenchymal stem cells (MSC) served as a human
non-malignant control. Indeed, MSC-conditioned medium did not cause PMNs to release NETs
(Figure 2). Fluorescent microscopy confirmed the release of NETs, as a stringy-like expulsion of exDNA
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can be visualised in AsPC-1 CM stimulated PMNs (Figure 3). At 3 h, PMA-stimulated PMNs show a
greater degree of web-like NETs due to PMA being a potent NET activator (Figure 3). To determine if
other NET components are present on AsPC-1 CM-induced NETs, neutrophil elastase was also stained.
Neutrophil elastase can also be seen extruded on NETs after incubation of PMN with AsPC-1 CM
(Figure 3). AsPC-1 CM stimulated PMNs were pre-treated with DNAse I, which resulted in significant
decrease in exDNA fluorescence (Figure A1), confirming the specificity of Sytox Green for exDNA.
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1:2 and NETs were quantified using Sytox Green (5 μM) in a fluorescence plate reader at (A) 30 min 
and (B) 3 h. AsPC-1 induced rapid NET release at 30 min while phorbyl myristate acetate (PMA)-
stimulated neutrophils (positive control) required 3 h. Control: unstimulated neutrophils. (n = 12, **** 
p < 0.0001 and ns = non-significant); One-way ANOVA followed by Bonferroni post-test. Data 
presented as mean ± SEM. 
Furthermore, to determine the nature of the NET-inducing factor/s, AsPC-1 CM was separated 
into protein and lipid fractions. As the optimal time for NET release induced by AsPC-1 was observed 
at 30 min, the lipid and protein fractions of AsPC-1 conditioned media were incubated with PMN for 
30 min before measuring NET release. Interestingly, the protein fraction of conditioned media 
resulted in almost 2-fold NET release, while the lipid fraction-stimulated PMNs did not (Figure 2), 
suggesting that AsPC-1-induced NETs are mediated by soluble proteins and do not rely on direct 
contact. 
 
Figure 2. AsPC-1 stimulates NET release via soluble protein mediators. (A) The conditioned media 
(CM) of AsPC-1 cells stimulated the release of NETs. Mesenchymal stem cell (MSC) CM, which served 
as a control for human non-malignant cells, did not stimulate NET release (n = 3, * p < 0.01 and ns = 
non-significant.); (B) AsPC-1 CM was separated into lipid and protein fractions, and each was 
incubated with neutrophils for 30 min. The protein fraction of AsPC-1 CM stimulated NET release 
while the lipid fraction did not. Media RPMI fractions served as control (n = 3). Control: unstimulated 
neutrophils. One-way ANOVA followed by Bonferroni post-test. Data presented as mean ± SEM. 
Figure 1. AsPC-1 stimulates the rapid release of neutrophil extracellular traps (NETs) from human
neutrophils. Human neutrophils were incubated with AsPC-1 cells at a neutrophil to AsPC-1 ratio of
1:2 and NETs were quantified using Sytox Green (5 µM) in a fluorescence plate reader at (A) 30 min and
(B) 3 h. AsPC-1 induced rapid NET release at 30 min while phorbyl myristate acetate (PMA)-stimulated
neutrophils (positive control) required 3 h. Control: unstimulated neutrophils. (n = 12, **** p < 0.0001
and ns = non-significant); One-way ANOVA followed by Bonferroni post-test. Data presented as
mean ± SEM.
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Figure 2. AsPC-1 stimulates NET release via soluble protein mediators. (A) The conditioned media
(C ) of AsPC-1 cells stimulated the release of NETs. esenchymal stem cell ( SC) C , which served
as a control for human non-malignant cells, did not stimulate NET release (n = 3, * p < 0.01 and
ns = non-significant.); (B) AsPC-1 CM was separated into lipid and protein fractions, and each as
incubated ith neutrophils for 30 in. The protein fraction of sP -1 sti ulated ET release
hile the lipid fraction did not. edia P I fractions served as control (n = 3). ontrol: unsti ulated
e tro ils. e- ay follo e by o ferroni post-test. ata resented as ean S .
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Figure 3. Confocal microscopy images of NETs induced by AsPC-1 conditioned media. (A) 
Neutrophils were incubated on poly-l-lysine coated glass slides and left either unstimulated, or were 
stimulated with PMA for 3 h, or AsPC-1 CM for 30 min. Neutrophils were fixed with 
paraformaldehyde and stained with Sytox (green) to visualise extracellular DNA. Images 
representative of three independent experiments; (B) AsPC-1 stimulated neutrophils were also 
stained with anti-elastase (pink) to visualise elastase bound on NETs. DAPI (blue) was also used as 
an alternative to visualise DNA. Elastase staining was above isotype control. Images representative 
of two independent experiments. Scale bar = 50 μm. 
2.3. AsPC-1-Induced NETs Do Not Require Reactive Oxygen Species Production 
Although the mechanism of the generation of NETs is poorly understood, several studies have 
established that the generation of reactive oxygen species (ROS) is required for the release of NETs 
[1,22,23]. To examine whether ROS production precedes NET generation in PMNs stimulated by AsPC-
1, levels of ROS were measured during PMN incubation with AsPC-1 CM using 2′,7′-
dichlorodihydrofluorescein diacetate (DCFDA) indicator dye. Surprisingly, ROS were not detectable in 
PMNs stimulated with AsPC-1 CM during the 30-min incubation period (Figure 4), the time at which 
significant AsPC1-induced NETs were observed, while PMA caused a significant accumulation in ROS 
at 3 h (Figure 4), suggesting that ROS generation is not required for AsPC-1-induced NET. To confirm 
the ROS-independent release of NETs, a ROS inhibitor, diphenyleneiodonium (DPI), was used to pre-
treat PMNs before incubation with AsPC-1 CM. Indeed, AsPC-1 NET release was not affected as 
exDNA remained unchanged after pre-treatment with DPI (Figure 4). On the other hand, NETs, as well 
as ROS generation, were significantly reduced to baseline levels in PMA-stimulated PMNs that were 
pre-treated with DPI (Figure 4). 
2.4. Platelets Primed by AsPC-1 Stimulate NET Release 
To determine whether platelets play a role in AsPC-1-induced NETs and could exacerbate the 
production of NETs, platelets were added to the PMN and AsPC-1 co-culture, and NET release was 
assessed. Platelets did not exacerbate NETs generated by AsPC-1, and unstimulated platelets did not 
cause NET release which was as expected in the context of normal physiological setting (Figure 5). 
Since the addition of platelets to the co-culture did not result in a further increase in NETs, we 
sought to determine if platelets needed pre-activation or priming with AsPC-1 before co-culturing 
with PMNs to have any effect on NETs formed. Hence, platelets were pre-incubated with AsPC-1 
cells for 4 h before incubating with PMNs. Interestingly, platelets that were primed with AsPC-1 cells 
caused PMNs to release NETs compared to unstimulated platelets (Figure 5). Furthermore, it was a 
rapid process that occurred in 30 min (Figure 5). On the other hand, collagen-stimulated platelets did 
not stimulate increased NET release (Figure 5). 
Figure 3. Confocal microscopy images of NETs induced by AsPC-1 conditioned media. (A) Neutrophils
were incubated on poly-l-lysine coated glass slides and left either unstimulated, or were stimulated
with PMA for 3 h, or AsPC-1 CM for 30 min. Neutrophils were fixed with paraformald hyd and
stained with Sytox (green) to visualise extracellula DNA. Images representative of three independent
experiments; (B) AsPC-1 stimulated neutrophils were also stained with anti-elastase (pink) to visualise
elastase bound on NETs. DAPI (blue) was also used as an alternative to visualise DNA. Elastase staining
was above isotype control. Images representative of two independent experiments. Scale bar = 50 µm.
Furthermore, to determine the nature of the NET-inducing factor/s, AsPC-1 CM was separated
into protein and lipid fractions. As the optimal time for NET release induced by AsPC-1 was observed
at 30 min, the lipid and protein fractions of AsPC-1 conditioned media were incubated with PMN for
30 min before measuri g NET release. Interestingly, the protein fraction of conditioned media resulted
in almost 2-fold NET release, while the lipid fraction-stimulated PMNs did not (Figur 2), suggesting
that AsPC-1-induced NETs are mediated by soluble proteins and do not rely on direct contact.
2.3. AsPC-1-Induced NETs Do Not Require Reactive Oxygen Species Production
Although the mechanism of the generation of NETs is poorly understood, several studies
have established that the generation of reactive oxygen species (ROS) is required for the release
of NETs [1,22,23]. To examine whether ROS production precedes NET generation in PMNs
stimulated by AsPC-1, levels of ROS were measured during PMN incubation with AsPC-1
CM using 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA) indicator dye. Surprisingly, ROS
were not detectable in PMNs stimulated with AsPC-1 CM during the 30-min incubation period
(Figure 4), the time at which significant AsPC1-induced NETs were observed, while PMA caused
a significant accumulation in ROS at 3 h (Figure 4), suggesting that ROS generation is not required
for AsPC-1-induced NET. To confirm the ROS-independent release of NETs, a ROS inhibitor,
diphenyleneiodonium (DPI), was used to pre-treat PMNs before incubation with AsPC-1 CM. Indeed,
AsPC-1 NET release was not affected as exDNA r mained unchanged after pre-treatment with DPI
(Figure 4). On the other hand, NETs, as well as ROS generation, were significantly reduced to baseline
levels in PMA-stimulated PMNs that were pre-treated with DPI (Figure 4).
Int. J. Mol. Sci. 2017, 18, 487 5 of 18
Int. J. Mol. Sci. 2017, 18, 487 5 of 17 
 
Figure 4. AsPC-1-induced-NET generation is independent of reactive oxygen species production. 
(A,B) Quantification of reactive oxygen species (ROS) generated during incubation with AsPC-1 CM 
and PMA at (A) 30 min and (B) 3 h using 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) 
fluorescent dye. ROS were not significantly generated in AsPC-1 CM-stimulated neutrophils at either 
time points; (B) PMA-stimulated neutrophils had significant ROS generated at 3 h, this was abolished 
with the addition of non-specific ROS inhibitor diphenyleneiodonium (DPI); (C,D) The effect of DPI 
on NET release in AsPC-1 or PMA-induced NETs; (C) DPI did not reduce AsPC-1-induced NETs; (D) 
NETs were significantly reduced in PMA-stimulated neutrophils by DPI. n = 3, ** p < 0.001, ns = non-
significant. One-way ANOVA followed by Bonferroni post-test. Data presented as mean ± SEM. 
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spreading assays. Platelets were then placed on a NET-coated slide and incubated for 1 h before 
staining the F-actin component of platelets with phalloidin-488, to assess the degree of adhesion and 
spreading of individual platelets. NETs caused significant adhesion and spreading of platelets as 
visualised by large spreading of F-actin of platelets across the NET-coated surface, compared to 
denatured-bovine serum albumin (BSA) coated surface, which served as negative control (Figure 6). 
Quantification of surface area coverage of platelet spreading also showed a significant increase in 
spreading on NET-coated slides (Figure 6). 
To further investigate which NET component was responsible for platelet adhesion and 
spreading, NET-coated slides were pre-treated with DNAse I before incubation with platelets. 
Although to a much lesser extent, platelets were still visualised adhering and spreading on NETs that 
were pre-treated with DNAse I (Figure 6). Analysis on quantification also found no significant 
decrease in surface area coverage with DNAse I (Figure 6), suggesting that the protein component in 
NETs are also capable of promoting platelet adhesion, activation and shape-change. 
Figure 4. AsPC-1-induced-NET generation is independent of reactive oxygen species production.
(A,B) Quantification of reactive oxygen species (ROS) generated during incubation with AsPC-1 CM
and P A at (A) 30 min and (B) 3 h using 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA)
fluorescent dye. ROS were not significantly generated in AsPC-1 CM-stimulated neutrophils
at either time points; (B) PMA-stimulated neutrophils had significant ROS generated at 3 h,
this was abolished with the addition of non-specific ROS inhibitor diphenyleneiodonium (DPI);
(C,D) The effect of DPI on NET release in AsPC-1 or PMA-induced NETs; ( ) DPI did not reduce
AsPC-1-induced NETs; (D) NETs were significantly reduced in PMA-stimulated neutrophils by DPI.
n = 3, ** p < 0.001, ns = non-significant. One-way ANOVA followed by Bonferroni post-test. Data
presented as mean ± SEM.
2.4. Platelets Primed by AsPC-1 Stimulate NET Release
To determine whether platelets play a role in AsPC-1-induced NETs and could exacerbate the
production of NETs, platelets were added to the PMN and AsPC-1 co-culture, and NET release was
assessed. Platelets did not exacerbate NETs generated by AsPC-1, and unstimulated platelets did not
cause NET release which was as expected in the context of normal physiological setting (Figure 5).
Since the addition of platelets to the co-culture did not result in a further increase in NETs,
we sought to determine if platelets needed pre-activation or priming with AsPC-1 before co-culturing
with PMNs to have any effect on NETs formed. Hence, platelets were pre-incubated with AsPC-1
cells for 4 h before incubating with PMNs. Interestingly, platelets that were primed with AsPC-1 cells
caused PMNs to release NETs compared to unstimulated platelets (Figure 5). Furthermore, it was a
rapid process that occurred in 30 min (Figure 5). On the other hand, collagen-stimulated platelets did
not stimulate increased NET release (Figure 5).
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Platelets (1 × 108/mL) were incubated with neutrophils and AsPC-1 cells. Platelets had no effect on 
AsPC-1-induced NETS; (B) the effect of AsPC-1-primed platelets on NET release. Platelets were 
primed with AsPC-1 cells by incubation with AsPC-1 for 4 h. The supernatant was removed and 
centrifuged to pellet platelets which were then resuspended and incubated with neutrophils. Primed 
platelets caused rapid NET release in 30 min. (n = 4, * p < 0.01, ** p < 0.001 and ns = non-significant. 
One-way ANOVA followed by Bonferroni post-hoc). Control: unstimulated neutrophils. Data 
expressed as mean ± SEM. 
2.6. NETs Are a Scaffold for Dynamic Platelet Adhesion and Thrombus Formation 
We next investigated the ability of platelets to adhere and activate on NETs and assessed 
thrombus formation under dynamic conditions. Since venous thrombosis is a common complication 
in pancreatic cancer patients, we conducted a whole blood perfusion assay over an NET-coated 
biochip with a venous shear stress of 10 dyne/cm2. Whole blood labelled with fluorescent  
dye DiOC6(3), was perfused over NET-coated channels for 10 min. Platelets were visualised  
as adhering, and thrombi were formed on NETs (Figure 7, Video S1, available online: 
https://www.dropbox.com/sh/qlmgmxptzqf4klj/AAA21i7NSjosAG9_zRDPSFxda?dl=0). A greater 
degree of platelet adhesion and thrombi were formed in collagen-coated channels (positive control), 
while denatured BSA-coated channels had negligible platelet adhesion (Figure 7; Videos S2 and S3 
Figure 5. AsPC-1-primed platelets, but not washed platelets, stimulate rapid release of NETs.
(A) Platelets (1× 108/mL) were incubated with neutrophils and AsPC-1 cells. Platelets had no effect on
AsPC-1-induced NETS; (B) the effect of AsPC-1-primed platelets on NET release. Platelets were primed
with AsPC-1 cells by incubation with AsPC-1 for 4 h. The supernatant was removed and centrifuged to
pellet platelets which were then resuspended and incubated with neutrophils. Primed platelets caused
rapid NET release in 30 min. (n = 4, * p < 0.01, ** p < 0.001 and ns = non-significant. One-way ANOVA
followed by Bonferroni post-hoc). Control: unstimulated neutrophils. Data expressed as mean ± SEM.
2.5. NETs Promote Static Platelet Adhesion and Activation
NETs have been shown to play a role in promoting thrombosis through studies in animal models
with venous thrombosis and through platelet and whole blood perfusion assays on NETs [24–26].
However, whether NETs are able to directly promote platelet adhesion and activate platelets in static
conditions has not been shown. To examine if NETs can directly promote the adhesion and activation
of platelets, NETs were isolated from PMA-stimulated PMNs and coated on glass slides for platelet
spreading assays. Platelets were then placed on a NET-coated slide and incubated for 1 h before
staining the F-actin component of platelets with phalloidin-488, to assess the degree of adhesion
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and spreading of individual platelets. NETs caused significant adhesion and spreading of platelets
as visualised by large spreading of F-actin of platelets across the NET-coated surface, compared to
denatured-bovine serum albumin (BSA) coated surface, which served as negative control (Figure 6).
Quantification of surface area coverage of platelet spreading also showed a significant increase in
spreading on NET-coated slides (Figure 6).
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Figure 6. NETs promote static platelet adhesion and activation. (A) NETs were isolated from PMA-
stimulated neutrophils before coated on glass slides. Washed platelets (2 × 107/mL) were incubated 
with NETs, and platelet adhesion and spreading were assessed using confocal microscopy. Denatured 
bovine serum albumin (dBSA)-coated slides served as negative control. NETs caused platelets to 
adhere and spread. The pre-treatment with deoxyribonuclease I (DNAse I) did not completely 
abrogate adhesion and spreading. Images representative of three independent experiments. Scale bar 
= 20 μm; (B) quantification of percentage area coverage of platelet adhesion and spreading using 
Image J analysis software. n = 3,* p < 0.05 and ns = non-significant. One-way ANOVA followed by 
Bonferroni post-hoc. Data presented as mean ± SEM. 
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Figure 7. NETs entrap and activate platelets and promote thrombus formation. (A) 2D confocal 
images of platelet adhesion and thrombus formation in collagen-, dBSA-, and NET-coated channels 
after perfusing DiO6C(3) fluorescently-labelled whole blood for 10 min at 10 dyne/cm2. Platelet 
adhesion and thrombi are visualised in NET-coated channels. Collagen- and dBSA-coated channels 
served as positive and negative controls, respectively. Scale bar = 90 μm; (B) Z-stack images confirm 
the presence of thrombi on NETs, which are similar to those in collagen-coated channels; (C) 
Quantification of surface area coverage of platelet adhesion showed a significant increase in NET-
coated channels. n = 3, * p < 0.05 unpaired t-test. 
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Fig re 6. NETs promote static platelet adhesion and activation. (A) NETs were isolated from
PMA-stimulated neutrophils before coated on gla s slides. W sh d platelets (2 × 107/mL) w re
incubated with NETs, an platelet adhesion and spre ding were assessed using c nf cal microscopy.
Denatur d bovine serum albumin ( BSA)-coated slides served as negative control. NETs caused
platelets to adhere and s read. The pre-treatment with deoxyribonuclease I (DNAse I) did not
completely abrogate adhesion and spreading. Images representative of three independent experiments.
Scale bar = 20 µm; (B) quantification of percentage area coverage of platelet adhesion and spreading
using Image J analysis software. n = 3,* p < 0.05 and ns = non-significant. One-way ANOVA followed
by Bonferroni post-hoc. Data presented as mean ± SEM.
To further investigate which NET component was responsible for platelet adhesion and spreading,
NET-coated slides were pre-treated with DNAse I before incubation with platelets. Although to a much
lesser extent, platelets were still visualised adhering and spreading on NETs that were pre-treated
with DNAse I (Figure 6). Analysis on quantification also found no significant decrease in surface area
coverage with DNAse I (Figure 6), suggesting that the protein component in NETs are also capable of
promoting platelet adhesion, activation and shape-change.
2.6. NETs Are a Scaffold for Dynamic Platelet Adhesion and Thrombus Formation
We next investigated the ability of platelets to adhere and activate on NETs and assessed thrombus
formation under dynamic conditions. Since venous thrombosis is a common complication in pancreatic
cancer patients, we conducted a whole blood perfusion assay over an NET-coated biochip with a
venous sh ar stres of 10 dyne/cm2. Whole blood labelled with fluorescent dye DiOC6(3), was perfused
over NET-c ated channels f r 10 min. Platelets were v sualised as adhering, and thrombi were formed
on NETs (Fig re 7, Video S1, available onlin : https://www.dropbox.com/sh/qlmgmxptzqf4klj/
AAA21i7NSjosAG9_zRDPSFxd ?dl=0). A gre t r degree of pl t let a hesion and thrombi were
formed in collagen-coated channels (positive control), while denatured BSA-coated cha nels had
negligible platelet adhesion (Figure 7; Videos S2 and S3 online). In addition, a significant increase
in surface area coverage by platelets was found in NET-coated channels compared to BSA-coated
channels (Figure 7). Z-stack images also showed 3D visualisation of thrombi that had formed on NETs,
similar to that present in collagen-coated channels, while thrombi were absent in BSA-coated channels
(Figure 7). Therefore, these data suggest that NETs are able to trap and activate platelets under venous
shear stress, and consequently promote thrombus formation.
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Figure 7. NETs entrap and activate platelets and promote thrombus formation. (A) 2D confocal images
of platelet adhesion and thrombus formation in collagen-, dBSA-, and NET-coated channels after
perfusing DiO6C(3) fluorescently-labelled whole blood for 10 min at 10 dyne/cm2. Platelet adhesion
and thrombi are visualised in NET-coated channels. Collagen- and dBSA-coated channels served as
positive and negative controls, respectively. Scale bar = 90 µm; (B) Z-stack images confirm the presence
of thrombi on NETs, which are similar to those in collagen-coated channels; (C) Quantification of
surface area coverage of platelet adhesion showed a significant increase in NET-coated channels. n = 3,
* p < 0.05 unpaired t-test.
3. Discussion
Pancreatic cancer (PaCa) is associated with high incidence of venous thromboembolism
(VTE) [27–29], which suggests a close interplay between PaCa cells and platelets, the latter being
a key player in haemostasis and thrombosis [30,31]. VTE in cancer is associated with a low survival
rate [32]. The high risk of VTE in PaCa patients is mainly associated with a generation of an intrinsic
hypercoagulable state [33]. Factors such as tumour-cell induced platelet aggregation, and increased
expression of procoagulant factors including tissue factor and thrombin, promote a prothrombotic state
which ultimately contributes to the development of VTE. In addition, platelet-neutrophil interactions
can coordinate VTE and various pathological conditions [26,34]. In the context of bacterial infection and
inflammation, activated platelets can induce NETs [14,35]. It has been known for years that platelet
activation is amplified in cancer [36]. In this study, we examined the interplay between platelets,
neutrophils and pancreatic cancer cells with a main focus on their impact on NET generation.
3.1. AsPC-1 Cells Can Induce NET Release
We first examined if pancreatic cancer cells can induce NET release. Here, we show that PaCa
AsPC-1 cells can stimulate PMNs to release NETs through direct contact and AsPC-1-derived soluble
proteins. Furthermore, we demonstrate that AsPC-1-induced NETs is a cancer specific phenomenon
that occurs rapidly and independently of ROS. We have previously shown that AsPC-1 cells in vitro
exhibit features that promote coagulation, such as tissue factor expression, and tissue factor-dependent
platelet aggregation (Figure A2), which can subsequently contribute to the development of VTE.
As NETs have been shown to promote thrombosis, in this study and by others, we propose that NETs
that are formed in response to PaCa cells may serve as an additional and novel contributor to the
development of VTE.
The release of NETs has been well-established to be a slow process requiring at least 3 to 4 h,
however few studies have reported a quick release of NETs occurring within the first hour [14,37].
Similarly, the generation of ROS is thought to be indispensable for forming NETs; however, a few
studies have also reported ROS-independent release of NETs [37–39]. The majority of NET-inducers
studied thus far, stimulate a NET-releasing mechanism that requires at least 3 h of stimulation and
is dependent on the generation of ROS [1,22,23]. Herein, we describe a novel mechanism induced
by AsPC-1, that is both rapid and ROS-independent. To date, one other study has described a NET
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mechanism that exhibited both rapid and ROS-independent mechanism of NET release, which was
induced by the Gram-positive bacteria Staphylococcus aureus [37]. Furthermore, Boone, et al. [40] have
recently studied NETs in PaCa in vivo, and reported that NETs released in PaCa are mediated through
autophagy pathways. Specifically, the receptor for advanced glycation end products (RAGE) which
mediates autophagy in PaCa was found to be necessary for NET release, as neutrophils from RAGE
knockout mice were less prone to release NETs. Thus, although we found that PaCa-induced NETs did
not depend on ROS generation, they may alternatively be dependent on autophagy which will need to
be investigated in future studies.
In addition to an early and ROS-independent release of NETs, we have demonstrated that
AsPC-1-induced NETs can be mediated by AsPC-1-derived soluble proteins. Potential mediators may
be inflammatory cytokines that are known to be increased in the serum of PaCa patients, and are also
released from PaCa cells such as interleukin (IL)-1β, IL-6, IL-8, tumour necrosis factor-alpha (TNF-α),
and transforming growth factor-β (TGF-β) [41]. The inflammatory cytokines, TNF-α, IL-8 and IL-1β,
have been previously shown to stimulate NET release [42]. Thus, these cytokines may collectively
contribute to the activation of PMN and release of NETs; however, further studies are required to
delineate the specific mediators. Other cytokines, particularly TGF-β may have a role in polarising
neutrophils to a pro-tumourigenic phenotype [43]. Recent studies suggest that neutrophils display
plasticity in the tumour microenvironment and can polarise from an N1 antitumour phenotype to
an N2 protumour phenotype by TGF-β [44]. Whether or not NET generation is a function of N2
protumour, and not N1 anti-tumour neutrophils, remains to be elucidated.
3.2. AsPC-1 Primed Platelets Favour NET Release Compared to Unstimulated Platelets
Neutrophil and platelet interactions are known to exist and play a role in infection and VTE [24].
Likewise, several studies have shown a major role of platelets in mediating interactions or releasing
mediators to stimulate NET release [14,15,35,45]. Most studies were carried out in the context of
bacterial infection. One study reported that lipopolysaccharide (LPS)-activated platelets were found
to mediate NETs, as inhibition of the LPS receptor significantly reduced platelet activation and NET
release [14]. Similarly, we observed a trend of increased NET generation when stimulated by platelets
that were primed with AsPC-1 cells (or AsPC-1-conditioned media, data not shown), compared
to unstimulated platelets. This was not observed when resting platelets were added to the PMN,
suggesting that the platelets required priming or pre-activation with AsPC-1 before they could have any
effect on PMN activation and NET release. As we have shown that AsPC-1-derived soluble proteins
can stimulate NET release, this suggests the potential role of exosomes (small vesicles containing
intracellular proteins and RNA) in mediating AsPC-1-induced NETs. Platelets can become ‘educated’
by tumour cells through the transfer of tumour-associated molecules such as proteins or RNA to
platelets [46–48]. Subsequently, we speculate that upon encounter with PMNs, tumour-educated
platelets may either transfer their contents to PMNs, or directly interact with PMNs to induce
NET release. Further studies are needed to confirm our observations, and to elucidate what factors
from AsPC-1-primed platelets are involved in NET generation. Future investigations may include:
(1) characterising of exosomes isolated from AsPC-1; (2) transcriptomic and proteomic profiling of
cancer-primed platelets; and (3) assessing the NET-stimulating capability of platelets isolated from
tumour-bearing mice.
On the other hand, NETs were not expected to be generated by unstimulated platelets as
neutrophil and platelets are constantly in contact within the systemic circulation, and spontaneous
NET generation would be undesirable, as it could potentially damage endothelial cells [49] and
promote unnecessary coagulation. Similarly, as collagen and platelets are known to play a role
in wound healing [50], excessive generation of NETs at a wound site due to collagen-activated
platelets is also undesirable, as it may hinder the wound healing process. However, Maugeri, et al. [51]
showed that collagen-activated platelets were able to induce NET release. The varying results may
be due to different NET quantification methods or number of neutrophils used for stimulation.
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Maugeri et al. [51] measured soluble DNA to quantify NETs which may have been a more sensitive
detection method than the one used here, and the authors also used 10-fold more neutrophils than in
our study. NETs generated at wound sites may cause a negative impact and become obstructive as
new matrix is deposited. Indeed, a study investigating the role of NETs in a diabetic mouse model,
known to have impaired wound healing, found excessive NETs being formed compared to normal
mice. Furthermore, degradation of NETs in these diabetic mouse models led to improvements in
wound healing [52]. Thus, the generation of NETs by activated platelets may be a regulated process
which is favoured in severe conditions where the immune response is compromised, such as in cancer
or bacterial infection.
3.3. NETs Activate Platelet Dynamics
We have shown for the first time that NETs can directly promote the adhesion, activation and
shape change of platelets in static conditions, which corroborates previous findings that NETs are a
scaffold for platelet adhesion and aggregation under dynamic conditions [24,25]. The adhesion and
activation of platelets was not entirely due to the DNA component of NETs, as the pre-treatment of
NETs with DNAse I did not completely abolish platelet adhesion and spreading. This suggests that
the protein component of NETs also contributes to platelet adhesion and activation. Histones are the
most abundant protein found on NETs [53], and therefore could possibly exert the greatest impact on
platelet activation amongst other NET proteins. Extracellular histones have been shown to activate
platelets, which in turn promote the generation of plasma thrombin and result in a procoagulant
phenotype [54]. Cathepsin G is also present on NETs and has been reported to promote platelet
aggregation in vitro [55]. The possible role of these proteins in promoting platelet activation will need
to be confirmed by re-assessing platelet adhesion, activation and spreading under the presence of
cathepsin G and histone inhibitors, or inhibitors that prevent the mechanism of histone-mediated
platelet activation.
We further extended our findings of platelet activation by NETs, and confirmed previous reports
by showing that thrombi can form on NETs under dynamic conditions. Our whole blood perfusion
assay over NETs was carried out under venous shear conditions, which implicates NETs as a scaffold
that can trap platelets and promote thrombus formation within the venous circulation, further
corroborating NETs as a mechanism that can contribute to VTE development. We did not investigate
the effects of DNAse I on the formation of thrombi under dynamic conditions; however, it will be
necessary to determine if DNAse I can serve as a viable drug to reduce VTE risks in pancreatic cancer
patients by dissolution of NETs, as we have shown that NETs can be stimulated by pancreatic cancer
cells, and can promote venous thrombosis. In addition, heparin may also provide some benefits as it is
known to prevent interactions between histones and platelets [56]. As suggested earlier, NET-bound
histones may play a major role in platelet activation and subsequent thrombi formation when released
in the context of cancer. Thus, heparin may provide additional benefits by reducing or preventing
cancer-associated thrombosis.
4. Materials and Methods
4.1. Neutrophil Isolation
A qualified phlebotomist under approved Curtin University Human Research Ethics Committee
number HR54/2014 collected blood from healthy volunteers using EDTA (5 mM) as an anticoagulant.
Neutrophils were isolated by density gradient centrifugation using PolymorphPrep (Axis-Shield,
Oslo, Norway) with minor changes to the manufacturer’s protocol. Briefly, blood was layered over
PolymorphPrep then centrifuged at room temperature for 35 min at 600× g. The layer containing
neutrophils was collected and washed twice at 4 ◦C in Hank’s buffered saline solution (without calcium
and magnesium). Contaminating red blood cells were lysed using Red Blood Cell Lysis buffer (Sigma,
St. Louis, MO, USA). Neutrophils were resuspended in ice-cold X-VIVO 15 media (Lonza, Basel,
Int. J. Mol. Sci. 2017, 18, 487 11 of 18
Switzerland) and kept on ice until ready for use in experiments. Cell viability was routinely >99% as
assessed by Trypan Blue exclusion. Cell purity was >93% as determined with a haematology analyser
(Mindray, Shenzhen, China; BC-VET2800) and flow cytometry staining for Cluster of Differentiation
66b (CD66b) (Figure A3).
4.2. Platelet Isolation
Platelets were isolated using the centrifugation method as previously described [57]. Briefly,
whole blood anticoagulated with acid citrate dextrose (ACD) was drawn from healthy volunteers
then centrifuged at room temperature for 20 min at 150× g to obtain platelet-rich plasma (PRP). PRP
was collected and platelets pelleted by centrifugation at room temperature for 10 min at 800× g.
The platelet pellet was washed three times in Citrate-Glucose-Sodium (CGS) buffer (123 mM NaCl,
33.3 mM glucose, 14.7 mM trisodium citrate, pH 7.0) before resuspending in HEPES Tyrode’s buffer
(5 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 5.5 mM glucose, 138 mM NaCl,
12 mM NaHCO3, 1.0 mM MgCl2·6H2O, 2.6 mM KCl, 0.36 mM NaH2PO4, pH 7.4) supplemented with
1.8 mM CaCl2 for use in experiments. Prostaglandin I2 (PGI2; 0.5 µM) was added to whole blood and
each wash to minimise platelet activation during the preparation process.
4.3. NET Quantification Assay
Neutrophils (5 × 104) were seeded in 96-well clear-bottom plate and allowed to adhere for 30 min
at 37 ◦C 5% CO2 before adding treatments, phorbol myristate acetate (PMA, 25 nM), AsPC-1 cells
(10 × 104), collagen (4 µg/mL), platelets (1 × 108/mL), or replacing the supernatant with AsPC-1
conditioned media. After 30 min incubation with treatment, NET release was quantified by staining
extracellular DNA with cell-impermeable Sytox® Green (5 µM; ThermoFisher, Waltham, MA, USA) and
measurement of fluorescence emission at 523 nm (488 nm laser excitation). Fluorescent measurement
was performed with EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). A second
reading was obtained at 3 h. Treatments were performed in replicates of three. The amount of NET
released was determined by calculating fluorescence fold change from unstimulated control.
4.4. Fluorescence Microscopy and Immunofluorescence
Neutrophils (1 × 106/mL) were seeded on poly-L-lysine-coated glass slides then incubated
with AsPC-1 conditioned media for 30 min, or PMA (25 nM) for 3 h at 37 ◦C. Extracellular DNA
was stained with cell-impermeable Sytox® Green (2 µM) before fixing the cells in 100% ice-cold
methanol for 5 min at room temperature. Samples were blocked in 10% goat serum for 30 min at
room temperature, then incubated with rabbit anti-elastase (1 µg/mL; Abcam #68672, Cambridge,
UK) in 1% bovine serum albumin (BSA) overnight at 4 ◦C. Rabbit IgG (Cell Signaling Technology,
Danvers, MA, USA) at the same concentration was used as an isotype control for anti-elastase antibody.
Cells were washed three times in phosphate-buffered saline (PBS) before incubating with anti-rabbit
Alexa594-conjugated secondary antibody (1/500; Cell Signalling). Samples were mounted with
ProLong Gold mounting media with DAPI (Molecular Probes, Life Technologies) and imaged using
Nikon A1+ confocal microscope.
4.5. Reactive Oxygen Species Quantification
Neutrophils (5 × 104) were seeded in 96-well black-bottom plate and allowed to incubate for
30 min in 37 ◦C 5% CO2, before pre-treating with a cell-permeant 2′,7′-dichlorodihydrofluorescein
diacetate (H2DCFDA, 10 µM; Sigma-Aldrich, St. Louis, MO, USA) for 15 min. H2DCFDA is a
non-fluorescent dye that is cleaved by intracellular esterases to a membrane-impermeable H2DCF,
which can subsequently react with a variety of reactive oxygen species to emit a highly fluorescent
2′,7′-dichlorofluorescein (DCF) [58]. Excess dye was removed and replaced with X-VIVO 15 media
(Lonza, Basel, Switzerland). Neutrophils were then either left untreated or pre-treated for 15 min with
ROS inhibitor diphenyleneiodonium (DPI; 1 µM). Neutrophils were finally treated with stimulants
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before measuring ROS fluorescence on an Enspire Multimode Plate Reader (PerkinElmer, Waltham,
MA, USA) at 523-nm fluorescence emission with 488-laser excitation. The quantity of ROS generated in
treated neutrophils was determined by calculated fluorescence fold change from unstimulated control.
4.6. Preparation of Conditioned Media
AsPC-1 cells (purchased from American Type Culture Collection, Mannassasa, VA, USA) were
grown in RPMI-1640 medium (ThermoFisher, Waltham, MA, USA) supplemented with 2 mM
L-glutamine, 10 mM HEPES (HyClone, ThermoFisher) 1 mM sodium pyruvate (Gibco, ThermoFisher),
4500 mg/L glucose, and 500 mg/L sodium bicarbonate and 10% fetal bovine serum (Bovogen, Victoria,
Australia), in an incubator maintained at 37 ◦C and 5% CO2. At 80%–90% confluence, the medium
was changed to phenol red-free RPMI-1640 without FBS, and cells were cultured for a further 36 h.
The supernatant (conditioned medium, CM) was collected and centrifuged at 12,000× g for 10 min at
4 ◦C to remove cell debris. CM was aliquoted and stored at −80 ◦C. Human primary mesenchymal
stem cells (MSC), obtained from Lonza (Basel, Switzerland), were similarly cultured in RPMI-1640
complete medium. Conditioned medium from MSC were prepared as above. Both cell lines were
negative for mycoplasma throughout all the studies (routine testing by Curtin Health Innovation
Research Institute, Perth, Australia).
4.7. Protein and Lipid Fractionation of Conditioned Media
The protein and lipid fractions were separated as described previously with slight
modifications [59]. Briefly, conditioned media were mixed with 100% butanol (1:2) and vortexed
before incubating at 4 ◦C for 90 min. After incubation, protein and lipid phases were separated by
centrifugation at 1000× g for 10 min. The lipid (upper) and protein (lower) phases were separated and
dried using a SpeedVac system (Eppendorf, Concentrator 5301, Hamburg, Germany) at 30 ◦C for 7 h.
The dry pellet was resuspended in PBS to 1/5 of the starting volume.
4.8. Cell-Free NET Isolation
NETs were isolated as previously described [60]. Briefly, neutrophils (5× 106/mL) were incubated
with 600 nM PMA for 4 h at 37 ◦C. The supernatant was removed and NET monolayer detached from
the culture surface with ice-cold PBS, then centrifuged at 400× g for 5 min at 4 ◦C to pellet cell debris.
The cell-free supernatant was pooled and centrifuged at 15,000× g for 15 min at 4 ◦C to pellet DNA.
DNA pellet was resuspended in PBS to a volume corresponding to 100 µL per 1 × 107 neutrophils to
obtain cell-free NETs.
4.9. Platelet Spreading Assay
Glass slides were coated with 1% denatured BSA (dBSA) in PBS or cell-free NET overnight at
4 ◦C in a humidifier chamber. NET-coated slides were either left untreated or pre-treated with DNAse
I (100 U/mL; Stemcell Technologies, Vancouver, BC, Canada) in Hank’s buffered saline solution
(with calcium). The coated slides were then washed with 1× PBS and blocked with 1% dBSA for
1 h at room temperature, in the humidifier chamber. Denatured BSA was prepared by heating the
solution in PBS without calcium or magnesium to 80 ◦C for 3 min, immediately put on ice until cool,
and aliquoted and stored at −20 ◦C until use.
Platelets (2 × 107/mL) were seeded on the coated slides for 1 h at 37 ◦C CO2 in the humidifier
chamber. Adherent platelets were washed with PBS before fixing in 4% paraformaldehyde for 10 min at
room temperature, permeabilised with 0.1% Triton-X 100 for 2 min, and washed once with PBS. Platelets
were then stained with Alexa Flour 488-conjugated phalloidin (diluted 1:100 in PBS, ThermoFisher,
Waltham, MA, USA) for 20 min in the dark. Samples were mounted with ProLong Gold antifade reagent
(Molecular Probes). Images were taken with Nikon A1+ confocal microscope with 100× objective.
Three random fields of view were taken for analysis using Image J software (Version 1.50i, National
Institute of Health, Bethesda, MD, USA).
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4.10. Perfusion Assay—Ex Vivo Thrombus Formation
Microfluidics biochip (Cellix Ltd., Dublin, Ireland) channels were coated with cell-free NETs,
1% dBSA or 100 µg/mL collagen type I overnight at 4 ◦C and blocked in 1% dBSA for 1 h.
Citrated-whole blood (1:9, 3.8% w/v sodium citrate to whole blood) was drawn from healthy volunteers
and fluorescently-labelled with DiOC6(3) (5 µM; Molecular Probes) for 15 min in the dark. Blood
was perfused through the channels at a venous shear rate of 10 dyne/cm2 for 10 min using a Mirus
microfluidics pump (Cellix Ltd.), after which the samples were washed at the same rate for 2 min in
PBS. Video live imaging of the perfusion and image snaps of formed thrombi were captured using
UltraView Vox spinning disk confocal microscope. Four fields of view were taken after each perfusion
assay for surface area quantification using Image J (Version 1.50i, National Institute of Health). Z-stack
images were also acquired.
4.11. Statistical Analysis
All statistical analysis was performed on GraphPad Prism 7 (GraphPad Software, Inc., San Diego,
CA, USA). Results are shown as mean ± SEM. The one-way ANOVA with post-hoc Bonferroni was
performed to determine statistical significance between means of multiple groups. The unpaired t-test
was used to compare means between two groups. p ≤ 0.05 was considered statistically significant.
5. Conclusions
Taken together, our results demonstrate that pancreatic cancer cells can stimulate NET
formation, and in turn NETs produced are a platform for platelet adhesion and thrombi formation.
The degradation of NETs by DNAse I, and/or prevention of histone-platelet interaction by heparin,
could become a potential new drug option for pancreatic cancer patients if proven effective to reduce
venous thrombosis, and may lead to improved survival rates as VTE is linked to poor prognosis in
PaCa patients. Moreover, since NETs have also been implicated in metastasis, targeting NETs may not
only reduce risk of developing VTE, but it may also attenuate the development of highly metastatic
pancreatic tumours. Thus, it will be important to look at the effects of NETs on pancreatic cancer
cell survival, proliferation, migration and invasion, to determine if NETs exhibit pro-tumourigenic
characteristics, and serve as another reason to be targeted in pancreatic cancer patients.
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Figure A2. AsPC-1 expresses tissue factor, and causes platelet aggregation (A) Light transmission 
aggregometry showed that AsPC-1-induced aggregation of human washed (HW) platelets, which 
was tissue factor-dependent, as addition of low-molecular-weight heparin (LMWH) prevented 
platelet aggregation. The downward-slope represents light transmission approaching 100%, which is 
indicative of platelet aggregation; (B) Flow cytometry analysis of AsPC-1 cells stained with anti-tissue 
factor show AsPC-1 expressing tissue factor above isotype control; (C) Phase-contrast images show 
platelets aggregating (black arrow) around AsPC-1 cells. 
 
Figure A3. Flow cytometry analysis of CD66b staining on isolated human neutrophils. (A) Forward-
side-scatter profile of isolated polymorphonuclear neutrophils (PMNs); (B) Isolated PMNs were 
stained with CD66b, a marker for PMNs, to determine purity of neutrophil isolation. A total of 93% 
of the isolated cell population was positive for CD66b. 
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PMNs were stained with CD66b, a marker for PMNs, to determine purity of neutrophil isolation.
A total of 93% of the isolated cell population was positive for CD66b.
References
1. Fuchs, T.A.; Abed, U.; Goosmann, C.; Hurwitz, R.; Schulze, I.; Wahn, V.; Weinrauch, Y.; Brinkmann, V.;
Zychlinsky, A. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 2007, 176, 231–241.
[CrossRef] [PubMed]
2. Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.S.; Weinrauch, Y.;
Zychlinsky, A. Neutrophil extracellular traps kill bacteria. Science 2004, 303, 1532–1535. [CrossRef] [PubMed]
3. Gupta, A.K.; Hasler, P.; Holzgreve, W.; Gebhardt, S.; Hahn, S. Induction of neutrophil extracellular DNA
lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum. Immunol. 2005, 66,
1146–1154. [CrossRef] [PubMed]
4. Hakkim, A.; Fürnrohr, B.G.; Amann, K.; Laube, B.; Abed, U.A.; Brinkmann, V.; Herrmann, M.; Voll, R.E.;
Zychlinsky, A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.
Proc. Natl. Acad. Sci. USA 2010, 107, 9813–9818. [CrossRef] [PubMed]
5. Yoo, D.-G.; Winn, M.; Pang, L.; Moskowitz, S.M.; Malech, H.L.; Leto, T.L.; Rada, B. Release of cystic fibrosis
airway inflammatory markers from pseudomonas aeruginosa-stimulated human neutrophils involves nadph
oxidase-dependent extracellular DNA trap formation. J. Immunol. 2014, 192, 4728–4738. [CrossRef] [PubMed]
6. Sur Chowdhury, C.; Giaglis, S.; Walker, U.A.; Buser, A.; Hahn, S.; Hasler, P. Enhanced neutrophil extracellular
trap generation in rheumatoid arthritis: Analysis of underlying signal transduction pathways and potential
diagnostic utility. Arthritis Res. Ther. 2014, 16, 1–14. [CrossRef] [PubMed]
7. Demers, M.; Krause, D.S.; Schatzberg, D.; Martinod, K.; Voorhees, J.R.; Fuchs, T.A.; Scadden, D.T.;
Wagner, D.D. Cancers predispose neutrophils to release extracellular DNA traps that contribute to
cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA 2012, 109, 13076–13081. [CrossRef] [PubMed]
8. Cools-Lartigue, J.; Spicer, J.; McDonald, B.; Gowing, S.; Chow, S.; Giannias, B.; Bourdeau, F.; Kubes, P.; Ferri, L.
Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Investig.
2013, 123, 3446–3458. [CrossRef] [PubMed]
9. Cedervall, J.; Zhang, Y.; Huang, H.; Zhang, L.; Femel, J.; Dimberg, A.; Olsson, A.-K. Neutrophil extracellular
traps accumulate in peripheral blood vessels and compromise organ function in tumor-bearing animals.
Cancer Res. 2015, 75, 2653–2662. [CrossRef] [PubMed]
10. Berger-Achituv, S.; Brinkmann, V.; Abed, U.A.; Kühn, L.I.; Ben-Ezra, J.; Elhasid, R.; Zychlinsky, A. A proposed
role for neutrophil extracellular traps in cancer immunoediting. Front. Immunol. 2013, 4, 48. [CrossRef]
[PubMed]
11. Arelaki, S.; Arampatzioglou, A.; Kambas, K.; Papagoras, C.; Miltiades, P.; Angelidou, I.; Mitsios, A.;
Kotsianidis, I.; Skendros, P.; Sivridis, E.; et al. Gradient infiltration of neutrophil extracellular traps in
colon cancer and evidence for their involvement in tumour growth. PLoS ONE 2016, 11, e0154484. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2017, 18, 487 16 of 18
12. Etulain, J.; Martinod, K.; Wong, S.L.; Cifuni, S.M.; Schattner, M.; Wagner, D.D. P-selectin promotes neutrophil
extracellular trap formation in mice. Blood 2015, 126, 242–246. [CrossRef] [PubMed]
13. Sreeramkumar, V.; Adrover, J.M.; Ballesteros, I.; Cuartero, M.I.; Rossaint, J.; Bilbao, I.; Nácher, M.; Pitaval, C.;
Radovanovic, I.; Fukui, Y.; et al. Neutrophils scan for activated platelets to initiate inflammation. Science
2014, 346, 1–12. [CrossRef] [PubMed]
14. Clark, S.R.; Ma, A.C.; Tavener, S.A.; Mcdonald, B.; Goodarzi, Z.; Kelly, M.M.; Patel, K.D.; Chakrabarti, S.;
Mcavoy, E.; Sinclair, G.D.; et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in
septic blood. Nat. Med. 2007, 13, 463. [CrossRef] [PubMed]
15. McDonald, B.; Urrutia, R.; Yipp Bryan, G.; Jenne Craig, N.; Kubes, P. Intravascular neutrophil extracellular
traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012, 12, 324–333. [CrossRef]
[PubMed]
16. Kraemer, B.F.; Campbell, R.A.; Schwertz, H.; Cody, M.J.; Franks, Z.; Tolley, N.D.; Kahr, W.H.A.; Lindemann, S.;
Seizer, P.; Yost, C.C.; et al. Novel anti-bacterial activities of β-defensin 1 in human platelets: Suppression
of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog. 2011, 7, 1–9.
[CrossRef] [PubMed]
17. Jurasz, P.; Alonso-Escolano, D.; Radomski, M.W. Platelet-cancer interactions: Mechanisms and pharmacology
of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 2004, 143, 819–826. [CrossRef] [PubMed]
18. Labelle, M.; Begum, S.; Hynes, R.O. Platelets guide the formation of early metastatic niches. Proc. Natl. Acad.
Sci. USA 2014, 111, 3053–3061. [CrossRef] [PubMed]
19. Kim, J.; Bae, J.-S. Tumor-associated macrophages and neutrophils in tumor microenvironment.
Mediat. Inflamm. 2016, 2016, 1–11. [CrossRef] [PubMed]
20. Ansari, D.; Ansari, D.; Andersson, R.; Andrén-Sandberg, A. Pancreatic cancer and thromboembolic disease,
150 years after trousseau. Hepatobiliary Surg. Nutr. 2015, 4, 325–335. [PubMed]
21. Tuveson, D.A.; Neoptolemos, J.P. Understanding metastasis in pancreatic cancer: A call for new clinical
approaches. Cell 2015, 148, 21–23. [CrossRef] [PubMed]
22. Lim, M.B.H.; Kuiper, J.W.P.; Katchky, A.; Goldberg, H.; Glogauer, M. RAC2 is required for the formation of
neutrophil extracellular traps. J. Leukoc. Biol. 2011, 90, 771–776. [CrossRef] [PubMed]
23. Kirchner, T.; Möller, S.; Klinger, M.; Solbach, W.; Laskay, T.; Behnen, M. The impact of various reactive
oxygen species on the formation of neutrophil extracellular traps. Med. Inflamm. 2012, 2012, 1–10. [CrossRef]
[PubMed]
24. Fuchs, T.A.; Brill, A.; Duerschmied, D.; Schatzberg, D.; Monestier, M.; Myers, D.D.; Wrobleski, S.K.;
Wakefield, T.W.; Hartwig, J.H.; Wagner, D.D. Extracellular DNA traps promote thrombosis. Proc. Natl.
Acad. Sci. USA 2010, 107, 15880–15885. [CrossRef] [PubMed]
25. Brill, A.; Fuchs, T.A.; Savchenko, A.S.; Thomas, G.M.; Martinod, K.; de Meyer, S.F.; Bhandari, A.A.;
Wagner, D.D. Neutrophil extracellular traps promote deep vein thrombosis in mice. J. Thromb. Haemost. 2012,
10, 136–144. [CrossRef] [PubMed]
26. Von Brühl, M.-L.; Stark, K.; Steinhart, A.; Chandraratne, S.; Konrad, I.; Lorenz, M.; Khandoga, A.;
Tirniceriu, A.; Coletti, R.; Köllnberger, M.; et al. Monocytes, neutrophils, and platelets cooperate to initiate
and propagate venous thrombosis in mice in vivo. J. Exp. Med. 2012, 209, 819–835. [CrossRef] [PubMed]
27. Cronin-Fenton, D.P.; Søndergaard, F.; Pedersen, L.A.; Fryzek, J.P.; Cetin, K.; Acquavella, J.; Baron, J.A.;
Sørensen, H.T. Hospitalisation for venous thromboembolism in cancer patients and the general population:
A population-based cohort study in denmark, 1997–2006. Br. J. Cancer 2010, 103, 947. [CrossRef] [PubMed]
28. Walker, A.J.; Card, T.R.; West, J.; Crooks, C.; Grainge, M.J. Incidence of venous thromboembolism in patients
with cancer—A cohort study using linked united kingdom databases. Eur. J. Cancer 2013, 49, 1404–1413.
[CrossRef] [PubMed]
29. Horsted, F.; West, J.; Grainge, M.J. Risk of venous thromboembolism in patients with cancer: A systematic
review and meta-analysis. PLoS Med. 2012, 9, e1001275. [CrossRef] [PubMed]
30. Delluc, A.; Rousseau, A.; Delluc, C.; Le Moigne, E.; Le Gal, G.; Mottier, D.; van Dreden, P.; Lacut, K.
Venous thromboembolism in patients with pancreatic cancer: Implications of circulating tissue factor.
Blood Coagul. Fibrinolysis 2011, 22, 295–300. [CrossRef] [PubMed]
31. Van den Berg, Y.W.; Osanto, S.; Reitsma, P.H.; Versteeg, H.H. The relationship between tissue factor and
cancer progression: Insights from bench and bedside. Blood 2012, 119, 924–932. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 487 17 of 18
32. Lee, A.Y.Y.; Levine, M.N. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003, 107,
17–21. [CrossRef] [PubMed]
33. Khorana, A.A.; Fine, R.L. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004, 5, 655–663.
[CrossRef]
34. Suzuki, K.; Sugimura, K.; Hasegawa, K.; Yoshida, A.; Suzuki, K.; Ishizuka, K.; Ohtsuka, T.; Honma, R.;
Narisawa, H.; Asakura, K. Activated platelets in ulcerative colitis enhance the production of reactive oxygen
species by polymorphonuclear leukocytes. Scand. J. Gastroenterol. 2001, 36, 1301–1306. [CrossRef] [PubMed]
35. Caudrillier, A.; Kessenbrock, K.; Gilliss, B.M.; Nguyen, J.X.; Marques, M.B.; Monestier, M.; Toy, P.;
Werb, Z.; Looney, M.R. Platelets induce neutrophil extracellular traps in transfusion-related acute lung
injury. J. Clin. Investig. 2012, 122, 2661–2671. [CrossRef] [PubMed]
36. Gay, L.J.; Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11,
123–134. [CrossRef] [PubMed]
37. Pilsczek, F.H.; Salina, D.; Poon, K.K.H.; Fahey, C.; Yipp, B.G.; Sibley, C.D.; Robbins, S.M.; Green, F.H.Y.;
Surette, M.G.; Sugai, M.; et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation
in response to staphylococcus aureus. J. Immunol. 2010, 185, 7413–7425. [CrossRef] [PubMed]
38. Rochael, N.C.; Guimarães-Costa, A.B.; Nascimento, M.T.C.; de Souza-Vieira, T.S.; Oliveira, M.P.;
Garcia e Souza, L.F.; Oliveira, M.F.; Saraiva, E.M. Classical ROS-dependent and early/rapid
ROS-independent release of neutrophil extracellular traps triggered by leishmania parasites. Sci. Rep. 2015,
5, 1–10. [CrossRef] [PubMed]
39. Kraaij, T.; Tengström, F.C.; Kamerling, S.W.A.; Pusey, C.D.; Scherer, H.U.; Toes, R.E.M.; Rabelink, T.J.;
van Kooten, C.; Teng, Y.K.O. A novel method for high-throughput detection and quantification of neutrophil
extracellular traps reveals ROS-independent net release with immune complexes. Autoimmun. Rev. 2016, 15,
577–584. [CrossRef] [PubMed]
40. Boone, B.A.; Orlichenko, L.; Schapiro, N.E.; Loughran, P.; Gianfrate, G.C.; Ellis, J.T.; Singhi, A.D.; Kang, R.;
Tang, D.; Lotze, M.T.; et al. The receptor for advanced glycation end products (rage) enhances autophagy and
neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther. 2015, 22, 326–334. [CrossRef] [PubMed]
41. Yu, J.H.; Kim, H. Oxidative stress and cytokines in the pathogenesis of pancreatic cancer. J. Cancer Prev. 2014,
19, 97–102. [CrossRef] [PubMed]
42. Keshari, R.S.; Jyoti, A.; Dubey, M.; Kothari, N.; Kohli, M.; Bogra, J.; Barthwal, M.K.; Dikshit, M. Cytokines
induced neutrophil extracellular traps formation: Implication for the inflammatory disease condition.
PLoS ONE 2012, 7, e48111. [CrossRef] [PubMed]
43. Fridlender, Z.G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G.S.; Albelda, S.M. Polarization of
tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 2009, 16, 183–194.
[CrossRef] [PubMed]
44. Sagiv, J.Y.; Michaeli, J.; Assi, S.; Mishalian, I.; Kisos, H.; Levy, L.; Damti, P.; Lumbroso, D.; Polyansky, L.;
Sionov Ronit, V.; et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer.
Cell Rep. 2015, 10, 562–573. [CrossRef] [PubMed]
45. Carestia, A.; Kaufman, T.; Rivadeneyra, L.; Landoni, V.I.; Pozner, R.G.; Negrotto, S.; D’Atri, L.P.; Gómez, R.M.;
Schattner, M. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap
formation mediated by activated platelets. J. Leukoc. Biol. 2016, 99, 153–162. [CrossRef] [PubMed]
46. Lakka Klement, G.; Yip, T.-T.; Cassiola, F.; Kikuchi, L.; Cervi, D.; Podust, V.; Italiano, J.E.; Wheatley, E.;
Abou-Slaybi, A.; Bender, E.; et al. Platelets actively sequester angiogenesis regulators. Blood 2009, 113,
2835–2842. [CrossRef] [PubMed]
47. Best, M.G.; Sol, N.; Kooi, I.; Tannous, J.; Westerman, B.A.; Rustenburg, F.; Schellen, P.; Verschueren, H.;
Post, E.; Koster, J.; et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass,
and molecular pathway cancer diagnostics. Cancer Cell 2015, 28, 666–676. [CrossRef] [PubMed]
48. Nilsson, R.J.A.; Balaj, L.; Hulleman, E.; van Rijn, S.; Pegtel, D.M.; Walraven, M.; Widmark, A.; Gerritsen, W.R.;
Verheul, H.M.; Vandertop, W.P.; et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011,
118, 3680–3683. [CrossRef] [PubMed]
49. Saffarzadeh, M.; Juenemann, C.; Queisser, M.A.; Lochnit, G.; Barreto, G.; Galuska, S.P.; Lohmeyer, J.;
Preissner, K.T. Neutrophil extracellular traps directly induce epithelial and endothelial cell death:
A predominant role of histones. PLoS ONE 2012, 7, 1–14. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 487 18 of 18
50. Murray, M.M.; Spindler, K.P.; Devin, C.; Snyder, B.S.; Muller, J.; Takahashi, M.; Ballard, P.; Nanney, L.B.;
Zurakowski, D. Use of a collagen-platelet rich plasma scaffold to stimulate healing of a central defect in the
canine ACL. J. Orthop. Res. 2006, 24, 820–830. [CrossRef] [PubMed]
51. Maugeri, N.; Campana, L.; Gavina, M.; Covino, C.; de Metrio, M.; Panciroli, C.; Maiuri, L.; Maseri, A.;
D’Angelo, A.; Bianchi, M.E.; et al. Activated platelets present high mobility group box 1 to neutrophils,
inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J. Thromb. Haemost. 2014,
12, 2074–2088. [CrossRef] [PubMed]
52. Roth Flach, R.J.; Czech, M.P. NETs and traps delay wound healing in diabetes. Trends Endocrinol. Metab. 2015,
26, 451–452. [CrossRef]
53. Urban, C.F.; Ermert, D.; Schmid, M.; Abu-Abed, U.; Goosmann, C.; Nacken, W.; Brinkmann, V.; Jungblut, P.R.;
Zychlinsky, A. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in
host defense against Candida albicans. PLoS Pathog. 2009, 5, e1000639. [CrossRef] [PubMed]
54. Semeraro, F.; Ammollo, C.T.; Morrissey, J.H.; Dale, G.L.; Friese, P.; Esmon, N.L.; Esmon, C.T. Extracellular
histones promote thrombin generation through platelet-dependent mechanisms: Involvement of platelet
TLR2 and TLR4. Blood 2011, 118, 1952–1961. [CrossRef] [PubMed]
55. Wilson, T.J.; Nannuru, K.C.; Sadanandam, A.; Singh, R.K.; Futakuchi, M. Cathepsin g enhances mammary
tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand. Cancer Res.
2008, 68, 5803–5811. [CrossRef] [PubMed]
56. Fuchs, T.A.; Bhandari, A.A.; Wagner, D.D. Histones induce rapid and profound thrombocytopenia in mice.
Blood 2011, 118, 3708–3714. [CrossRef] [PubMed]
57. Carrim, N.; Arthur, J.F.; Hamilton, J.R.; Gardiner, E.E.; Andrews, R.K.; Moran, N.; Berndt, M.C.; Metharom, P.
Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated
receptor 4 and GPIbα. Redox Biol. 2015, 6, 640–647. [CrossRef] [PubMed]
58. Lü, J.-M.; Lin, P.H.; Yao, Q.; Chen, C. Chemical and molecular mechanisms of antioxidants: Experimental
approaches and model systems. J. Cell. Mol. Med. 2010, 14, 840–860. [CrossRef] [PubMed]
59. Ho-Tin-Noe, B.; le Dall, J.; Gomez, D.; Louedec, L.; Vranckx, R.; El-Bouchtaoui, M.; Legres, L.;
Meilhac, O.; Michel, J. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-γ
trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ. Res. 2011, 109, 1003–1067.
[CrossRef] [PubMed]
60. Najmeh, S.; Cools-Lartigue, J.; Giannias, B.; Spicer, J.; Ferri, L.E. Simplified human neutrophil extracellular
traps (NETs) isolation and handling. J. Vis. Exp. 2015, 98, e52687. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
